Online inquiry

IVTScrip™ mRNA-Anti-TNFRSF4, MEDI0562(Cap 1, 5-Methyl-CTP, 30 nt-poly(A))   (CAT#: GTTS-WQ11194MR)

This product GTTS-WQ11194MR is a type of mRNA having 30 nt poly(A) tail and modified with Cap 1 & 5-Methyl-CTP. It ecodes the monoclonal antibody that targets TNFRSF4 gene. The antibody can be applied in Solid tumors research.
Specifications
Product type mRNA
Modified bases 5-Methyl-CTP
5' Cap Cap 1
Species Chimeric; Humanized
RefSeq NM_003327.4
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 7293
UniProt ID P43489
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-TNFRSF4, MEDI0562(Cap 1, 5-Methyl-CTP, 30 nt-poly(A)) (GTTS-WQ11194MR). Click the button above to contact us or submit your feedback about this product.

See other products
CAT Product Name Product Type CDs
GTTS-WQ7914MR IVTScrip™ mRNA-Anti-CSF2, GSK3196165(Cap 1, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA GSK3196165
GTTS-WQ10229MR IVTScrip™ mRNA-Anti-RHD, LFB-R593(Cap 0, 2-Thio-UTP, 30 nt-poly(A)) mRNA LFB-R593
GTTS-WQ15997MR IVTScrip™ mRNA-Anti-ERBB2, ZW-25(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA ZW-25
GTTS-WQ13912MR IVTScrip™ mRNA-Anti-INHBA, REGN2477(Cap 0, Pseudo-UTP, 30 nt-poly(A)) mRNA REGN2477
GTTS-WQ13502MR IVTScrip™ mRNA-Anti-SNCA, PRX002(Cap 1, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA PRX002
GTTS-WQ6881MR IVTScrip™ mRNA-Anti-CX3CL1, E-6011(Cap 0, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA E-6011
GTTS-WQ13456MR IVTScrip™ mRNA-Anti-ERBB2&TNFRSF9, PRS-343(Cap 1, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA PRS-343
GTTS-WQ7962MR IVTScrip™ mRNA-Anti-IL7R, GX-17(Cap 1, Pseudo-UTP, 120 nt-poly(A)) mRNA GX-17
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW